Hidden costs of non-adherence in Clinical Trials
Tools for combatting persistance and compliance issues
In the United States, patient adherence with chronic medications averages only 50%. It has been estimated that nonadherence to prescribed medications causes nearly 125,000 deaths annually
Patients’ non-adherence impact in general populations and during clinical trials - challenges and solutions
Human subject non-adherence during clinical trials remains, to this day, neither undetected nor adequately and scientifically validated, and whether non-adherence is purpose-based or not, it remains a serious threat to an acceptable clinical result.
Patient Nonadherence in Clinical Trials:
Could There Be a Link to Postmarketing Patient Safety?
Undetected poor adherence or failure to increase sample size to maintain the power of the study can result in overestimation of the dosage and underestimation of the adverse event profile. Patients in the general population will be at risk if they take the study dose but have a higher rate of patient adherence than the study participants in the clinical trial.
Benefits of smart packaging
Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
Patient adherence is a principal concern in comprehensive patient care. Nonadherence is a primary reason why full treatment benefits are not realized. In addition to the clinical ramifications, it is estimated that the overall cost of medication nonadherence ranges from $100 billion to $300 billion per year, further quantifying the problem of nonadherence
Mitigating the Effects of Nonadherence
in Clinical Trials
Statistical analyses of nonadherence data, novel protocol design, and the use of biomarkers, subject registries, and/or medication adherence technologies.
Monitor individual subject adherence with a medication adherence technology, not pill counts alone;when appropriate, provide subjects and investigators with prompt feedback when nonadherence is detected.
IT in Practice: how "smart" packaging can help with medication adherence
Smart Packaging are centred on the use of medicines. It is then essential that the pharmacy profession takes the lead on their implementation. It is to be hoped that pharmacists will be able to debate the issues concerning these technologies and form a consensus about their use before they are introduced by major healthcare providers.
Medicodose in the news
Patient-Centric Methods for Tackling Clinical Trial IP Nonadherence
Published in Applied Clinical Trials
Nadir Benouali, Founder & President of MEDICODOSE Systems, will elaborate on his perspectives regarding the causes and issues of IP nonadherence, what the pharmaceutical industry is doing to tackle IP nonadherence, patient-centric and site friendly solutions to addressing IP nonadherence
Medicodose, pionnier de l’emballage intelligent
Published by La Tribune
L’entreprise basée à Marseille entend révolutionner le monde des essais cliniques en transformant la tablette de médicaments en objet connecté. Une solution qui permettrait aux acteurs de la santé, groupes pharmaceutiques en tête, de réaliser des économies se chiffrant en millions d’euros.
L'emballage, un remède au service de notre santé
Published by InvestInProvence
Nadir Benouali, spécialisé dans le management des médicaments pendant plus de 20 ans aux USA, parcourt les hôpitaux du monde. Partout, on lui expose le problème de la non-adhérence des patients envers leurs traitements !